LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities
Genes & Development · 2023-11 · 37 (21-24) · 948-967
DOI: 10.1101/gad.351051.123 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes & Development, online erschienen am 13.12.2023. Verfasst von Carlos Mendez-Dorantes und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; kathleenh_burns@dfci.harvard.edu carlos_mendez-dorantes@dfci…. Hauptthemen laut MEDLINE: Long Interspersed Nucleotide Elements, Neoplasms. Die Arbeit wurde bisher 125-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Long interspersed element 1 (LINE-1) is the only protein-coding transposon that is active in humans. LINE-1 propagates in the genome using RNA intermediates via retrotransposition. This activity has resulted in LINE-1 sequences occupying approximately one-fifth of our genome. Although most copies of LINE-1 are immobile, ∼100 copies are retrotransposition-competent. Retrotransposition is normally limited via epigenetic silencing, DNA repair, and other host defense mechanisms. In contrast, LINE-1 overexpression and retrotransposition are hallmarks of cancers. Here, we review mechanisms of LINE-1 regulation and how LINE-1 may promote genetic heterogeneity in tumors. Finally, we discuss therapeutic strategies to exploit LINE-1 biology in cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; kathleenh_burns@dfci.harvard.edu carlos_mendez-dorantes@dfci.harvard.edu.
- Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA.
- Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
ORCID-Profile: Carlos Mendez-Dorantes, Kathleen H Burns
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- National Institutes of Health
- Dana-Farber Cancer Institute
- Jane Coffin Childs Memorial Fund for Medical Research
Zitieren
APA
Mendez-Dorantes, C., & Burns, K. H. (2023). LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities. Genes & Development, 37(21-24), 948-967. https://doi.org/10.1101/gad.351051.123
Vancouver
Mendez-Dorantes C, Burns KH. LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities. Genes & Development. 2023;37(21-24):948-967. doi:10.1101/gad.351051.123
BibTeX
@article{MendezDorantes2023,
author = {Mendez-Dorantes, Carlos and Burns, Kathleen H},
title = {LINE-1 retrotransposition and its deregulation in cancers: implications for therapeutic opportunities},
journal = {Genes & Development},
year = {2023},
volume = {37},
number = {21-24},
pages = {948--967},
doi = {10.1101/gad.351051.123}
}
EUVIMED